Welcome to BioSeeker Group!

Triple Analysis: Leukemia, Angiogenesis and Cancer Vaccines

Additional Information

Published Date Mar 19, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3858
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Leukemia, Angiogenesis and Cancer Vaccines in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in Leukemia and by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Angiogenesis and Cancer Vaccines.

    To find out more about Triple Analysis: Leukemia, Angiogenesis and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Angiogenesis and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in Leukemia and by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia
5.1 The Scope of this Report 29
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140
Figures: Includes 6 Figures
Tables: Includes 253 Tables
Total Number of Pages: 1,147

Part II: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

Part III: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

This Report Includes the Following Companies:
3M Pharmaceuticals
4SC
Abbott
Abiogen
AC Immune
Acceleron Pharma
Access
Actinium Pharmaceuticals
Active Biotech
Adaptimmune
Adherex
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Agennix
Agenus
Aida Pharmaceuticals
Alexion
Alfa Wassermann
Alnylam
AlphaVax
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amphora
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisoma
Anza Therapeutics
Arana Therapeutics
Arca biopharma
Argos Therapeutics
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Asahi Kasei Pharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
Bavarian Nordic
Bayer
Bellicum Pharmaceuticals
Bio-Path Holdings
BioAlliance Pharma
BioAxone
Biocad
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
BioNTech
BioSante
Biostar
Bioton
BioVex
Boehringer Ingelheim
Bolder BioTechnology
BreakThrough Therapeutics
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cancer Advances
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Center of Molecular Immunology
Cephalon
CG Therapeutics
ChemoCentryx
Chemokine Therapeutics
China Sky One Medical
Choongwae
Circadian Technologies
CJ Corp
Clavis Pharma
Cornerstone Pharmaceuticals
Cosmo Pharmaceuticals
CreaGene
CSL
Cue Biotech
Curacyte
CureTech
CureVac
Curis
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytochroma
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Dong-A
Dyax
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Epizyme
Erimos
Esperance Pharmaceuticals
Etubics
Exelixis
ExonHit Therapeutics
Five Prime Therapeutics
Galena Biopharma
GammaCan
Gemin X Biotechnologies
Genencor
Genentech
Generex
Genmab
GenOdyssee Pharmaceuticals
Genta
Genticel
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlobeImmune
GlycoGenesys
GlycoMimetics
Gradalis
Green Cross
Hanmi
Hayashibara
Heat Biologics
Heber Biotec
Hemispherx Biopharma
Hoffmann-La Roche
Hy BioPharma
Ichor Medical Systems
Idera Pharmaceuticals
IDM Pharma
IkerChem
ImClone Systems
immatics biotechnologies
Immune Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoFrontier
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
ImmuPharma
Incyte Corporation
InDex Pharmaceuticals
Inex
Innate Pharma
Innovive
Inovio
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Introgen Therapeutics
ISA Pharmaceuticals
Isis Pharmaceuticals
Italfarmaco
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
KAI Pharmaceuticals
KaloBios
Kanisa
Karus Therapeutics
Kinex
Kirin Pharma
Kringle Pharma
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
Mannkind
MAT Biopharma
MaxCyte
MaxoCore Pharmaceuticals
Meda
MediGene
Memgen
Menarini
Merck & Co
Merck KGaA
Mersana Therapeutics
MethylGene
Micromet
MolMed
Mologen
Momotaro-Gene
Morvus Technology
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
NewSouth Innovations
NIH
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novartis
NovaRx
Novelix
Novogen
Noxxon
Oasmia
OncoMune
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Onyvax
Orchestra Therapeutics
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
OXiGENE
Pepscan Therapeutics
Peptagen
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmacopeia
Pharmacyclics
PharmaForm
PharmaMar
Pharmexa
Pharminox
Philogen
PhiloGene
PIERIS Proteolab
Pierre Fabre
Piramal
Portola Pharmaceuticals
Prochon Biotech
Progen
Progenics Pharmaceuticals
ProMetic Life Sciences
Protein Sciences
Protgen
Protherics
PTC Therapeutics
Radient Pharmaceuticals
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Reliance Life Sciences
responsif
Rexahn
Rigel
Sangamo BioSciences
Sanofi
Sanofi-Aventis
Santaris Pharma
Sarepta Therapeutics
Sareum
SBI Biotech
SBIO
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Semafore Pharmaceuticals
Sepal Pharma
Servier
Shenogen
Shionogi
Shire
Sidus
Simcere Pharmaceuticals
Southern Research Institute
Spear Therapeutics
Spirogen
SRI International
Stainwei Biotech
Stemline Therapeutics
SuperGen
Swedish Orphan Biovitrum
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Synageva BioPharma
SynDevRx
Synta Pharmaceuticals
Syntrix
Taiho
Takeda
Talon Therapeutics
TapImmune
Targa Therapeutics
TargeGen
Tau Therapeutics
TeGenero
Teva
Therion Biologics
ThromboGenics
Tigris Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
Transgene
Trion Pharma
UCB
United Biomedical
Vaccinex
Valeant
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
VBL Therapeutics
Vectura
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest Pharmaceuticals
Viragen
Virionics
ViroMed
XBiotech
Xencor
Xerion
Yamasa Corporation
Zensun
Zenyaku Kogyo
Zydus Cadila
A Shortlist of Drugs Included are:
A6
abagovomab
ABT-510
ADXS11-001
AE-37
aflibercept
AGS-003
alemtuzumab
AMG-386
amonafide malate
amsacrine
Angiozyme
ANZ-207
apatinib
ARQ-197
astuprotimut-r
atrasentan
Auto TAG vaccine
AVX-701
axitinib
barasertib
belagenpumatucel-L
belinostat
bevacizumab
BIBF-1120
bisantrene
BMS-690514
bosutinib
BP-GMAX-CD1
brivanib alaninate
BV-NSCLC-001
CB-10-01
CDX-1307
cediranib
CG-201
cilengitide
cladribine
clofarabine
CreaVax-PC
CSF-GM
CV-9103
CV-9201
CVac
cytarabine ocfosfate
cytarabine, injectable
dasatinib
daunorubicin
DCVax-prostate
decitabine
DI-17E6
dovitinib lactate
E-75
E-7820
elacytarabine
emepepimut-S
endostatin
ENMD-2076
enocitabine
enzastaurin hydrochloride
everolimus
Exherin
foretinib
fosbretabulin tromethamine
gemtuzumab ozogamicin
GI-4000
GliaAtak
GSK-2130579A
GT-111
GV-1001
GVAX
GVX-3322
HBP-347
Her-2/Neu peptides
Hi-8 MEL
histamine dihydrochloride
HS-110
icrucumab
ICT-107
idarubicin
imatinib mesilate
imMucin
IMO-2055
interferon
interferon (alpha-N1)
interferon (alpha)
interferon (alpha2)
interferon (alpha2a)
interferon (alpha2b)
interferon (alpha2c)
interferon (gamma)
interferon alpha-2b
interleukin-12
intetumumab
IPP-204106
ISA-P53-01
JI-101
JX-594
lenvatinib
lestaurtinib
leukemia vaccine
linifanib
lumiliximab
LY-2275796
MDX-1379
MGCD-265
MGN-1601
midostaurin
mitoxantrone
motesanib diphosphate
muparfostat (IV)
MVA-BN Her-2 vaccine
NGR-TNF
nilotinib
obinutuzumab
oblimersen sodium
ofatumumab
ON-01910
OncoVAX
Onyvax-105
OTS-102
p.DOM-WT1-37/p.DOM-WT1-126 DNA
paclitaxel
PancAtak
pazopanib hydrochloride
PCI-27483
pegdinetanib
peginterferon alfa-2b
pentostatin
PF-4856884
plitidepsin
poly-ICLC
polyclonal antibody stimulator
ponatinib
ProstAtak
PROSTVAC
PSMA ADC
PTC-299
RAF-265
ramucirumab
razoxane
regorafenib
Reximmune-C
rhIFN-alpha
ridaforolimus
rindopepimut
rintatolimod
rituximab
S-488410
SCIB-1
sipuleucel-T
sirolimus
sobuzoxane
sorafenib tosylate
SU-6668
sunitinib malate
Survivac
talactoferrin alfa
tamibarotene
TAS-102
tasquinimod
TB-403
telatinib
Tenarad
teniposide
TG-4010
thymalfasin
tipapkinogene sovacivec
tipifarnib
tivozanib
TRC-105
TroVax
vandetanib
velimogene aliplasmid
verpasep caltespen
vismodegib
vitespen
volociximab
vosaroxin
VX-001
XL-184
XL-647
zorubicin

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Angiogenesis and Cancer Vaccines.
    To find out more about Triple Analysis: Leukemia, Angiogenesis and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Angiogenesis and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Colorectal Cancer, Lymphoma and Antibodies
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lymphoma and by the compound strategy of Antibodies. Learn More


Competitive Outlook on Non-Antibody Based Cancer Vaccines
Research and development in the cancer vaccine field is dominated by its top 10 players, interestingly not including any of the big pharma companies per se. The recent Gardasil approval and GlaxoSmithKline’s acquisition of Corixa will certainly push the industry towards more acquisitions. With this in mind, this report makes an in-depth assessment of competitive landscape, tumor antigen technologies, immunostimulatory strategies, vaccine delivery technologies, and a progress analysis of six major cancer vaccine indications. Learn More

Other selected research from the 'Oncology' category:


Bladder Cancer Drug Pathway Analyzer
There are today at least 141 targeted molecular therapies known to affect more than 219 specific intracellular signaling pathways for the treatment of bladder cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 133 drug targets that are included in this drug-pathway analyzing tool. No less than 123 of these have been recorded with mutations and 30 drug targets have mutations which have been causally implicated in cancer. Learn More


Triple Analysis: Lymphoma, Melanoma and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More